INTRODUCTION
============

Transrectal ultrasound-guided prostate needle biopsy (TPB) under local anesthetic is the most common technique used to assess for prostate cancer. Studies estimate that nearly 1 million are performed in the United States each year \[[@B1]\]. Historically, TPB has a low infection risk (less than 1%) when done using recommended fluoroquinolone prophylaxis. Rates of post-TPB infection have increased to 6% with more men requiring hospitalization due to related sepsis over the last decade \[[@B2]\].

The cause of the rising infection rates is due to the rapid increase in fluoroquinolone-resistant (FQR) *Escherichia coli*. These resistant bacteria are colonized in the rectum in 15% to 22% of men at the time of prostate biopsy \[[@B3]\]. The rising incidence of infections has led urologists to either switch to non-fluoroquinolone antibiotic prophylaxis or add more antibiotics, despite an absence of supporting evidence. The concern is that multiple broad-spectrum antibiotics used for a single outpatient procedure may worsen the current critical issue of antibiotic resistance. We utilize a "targeted prophylaxis" approach by obtaining a rectal culture 1 to 2 weeks before the biopsy to direct alternative prophylaxis \[[@B4]\]. We now can detect those men colonized with FQR *E. coli* before a prostate biopsy.

Our objective was to evaluate the gut microbiome of individuals positive or negative for FQR *E. coli* to identify bacterial members associated with resistance to FQR colonization. The results could have future implications for reducing FQR before prostate biopsy and reducing infections by non-antibiotic means.

MATERIALS AND METHODS
=====================

1. Study design
---------------

The study is an observational study to investigate the microbiome differences in men with and without FQR organisms found on rectal culture. A rectal swab was performed on men before an upcoming prostate biopsy procedure as standard of care to perform "targeted prophylaxis." The culturette had two cotton swabs per sample. We sent one swab to microbiology as standard protocol. The second swab was being stored in a 15 mL conical tube with phosphate-buffered saline (PBS) and transferred to our lab for microbiome processing in our genomics core. Rectal swabs have been determined equivalent to stool culture and are easier to obtain in the office, which improves protocol compliance \[[@B5]\]. Moreover, rectal swabs will be able to be extrapolated to clinical practice. We queried patients and their charts regarding antibiotic exposure in the past year.

2. Population
-------------

After institutional review board (IRB) approval (approval number: 05-234H) to obtained rectal swabs stored in our genitourinary biorepository for microbiome collection. Men presented to the South Texas Veterans Health Care System Audie Murphy Division Hospital for evaluation for a "for cause" biopsy usually consisting of elevated PSA or abnormal prostate exam. After shared decision making, the patient and physician determined the indication for a biopsy and the patient would undergo a rectal swab collection to investigate for colonization of FQR *E. coli* as the standard of care. Physicians chose antibiotic prophylaxis that included ciprofloxacin as baseline and targeted augmented prophylaxis to all patients with fluoroquinolone resistance. We requested banked genitourinary biorepository rectal swabs for research with IRB approval to access the specimens with associated demographics and particularly any antibiotic use in the last year. Those men currently using antibiotics were excluded.

3. Rectal culture
-----------------

The Liquid Stuart Medium swab and transport system (Copan Diagnostics, Murrieta, CA, USA) was obtained at the time of standard digital rectal examination of the prostate and sent to microbiology. The microbiology lab inoculates the swab onto MacConkey agar containing 10 µg/mL of ciprofloxacin (Hardy Diagnostics, Santa Maria, CA, USA). As a control, the sample was also inoculated onto regular MacConkey agar to ensure that enteric bacteria were indeed on the swab. If after the 24-hour incubation there was no growth on the ciprofloxacin-infused MacConkey agar and there was a growth of normal flora on the other agars, the rectal flora was assumed to be ciprofloxacin-susceptible. Conversely, any Gram-negative (GN) rods growing on the ciprofloxacin-infused MacConkey agar were presumed to be ciprofloxacin-resistant. We analyzed a representative of each distinct colony morphotype using the Vitek 2 analyzer (BioMerieux, Durham, NC, USA) for identification by GN cards and sensitivity testing by antibiotic susceptibility testing cards using Clinical and Laboratory Standards Institute Interpretative Criteria \[[@B6]\].

4. DNA isolation
----------------

After collection, the rectal swab is placed in 500 microliters of PBS in a sterile 15 mL conical tube to rinse off the particulate stool. The stool slurry is then transferred to a 1.7 mL microcentrifuge tube. The stool slurry is centrifuged at 12,000g for 5 minutes and the volume of PBS is reduced to 200 microliters. The DNA is subsequently isolated from the 200 microliters of stool specimen using the QIAamp Fast DNA Stool Mini Kit (Qiagen, Valencia, CA, USA).

5. Microbiome
-------------

Genomic DNA was quantified and the V1--V2 variable region of the 16S rRNA genes amplified with custom-designed primers (F27/R355). The forward Bosshard sequence was AGAGTTTGATCMTGGCTCAG (27F) and the reverse Bosshard sequence was GCTGCCTCCCGTAGGAGT (355R) with the amplicon size of V1--V2 about 320 bp (355-27). Libraries for all samples were prepared and sequenced by Paired-end sequencing (2×300 bp) using the Illumina MiSeq platform. Raw sequences were quality trimmed (Q20) by sickle, and reads shorter than 200 bases were removed. Therefore, only the forward read was used for this analysis. The trimmed sequences were exported as FASTA files.

### 1) Sample size calculation

Power calculations for 16S amplicon and whole-genome shotgun microbiome studies are particularly challenging, as there is limited uniform data to analyze and uncertainty in the distribution of bacterial taxa throughout the human population \[[@B7]\]. The Human Microbiome Project (HMP) has released a large uniform 16S amplicon survey of gut-associated samples from healthy individuals \[[@B8][@B9][@B10]\]. This publicly available data serves as a potential resource for power-analyses by allowing for empirical calculation of the expected variability of taxa in the healthy distal gut microbiome. We obtained taxonomic annotations from 16S profiles of 146 HMP fecal samples and examined the variability of genera among individuals. After subsampling read sets to achieve equivalent sequencing depth across all sample, we identified 27 genus-level groups that on average each represented at least 0.5% of 16S sequences from the gut microbiome. We then computed the associated variance in relative abundance for each of these 27 genera, and used the empirical values to perform a comprehensive power-analysis. For each genus, we estimated the power for a range of proportional shifts in average relative abundance. As expected, increased statistical power was found with higher abundance genera, so here we focus on power results for organisms reflecting an average of 0.5% to 1.0% of 16S sequences in the gut microbiome because detecting differences in these rare taxa may be critical to our study. Among the 10 genera found at this low level in the HMP data, if we assume equal variance in two normally-distributed treatment populations, and require a significance level of α=0.05, we expect that with at least 15 samples per treatment group, we will be able to detect a relative increase of a factor of 4 (e.g., 0.5% mean abundance increased to 2.5%, or 1% mean abundance increased to 5%), with a statistical power of 93.8%. Considering the genera with average frequency of 1% to 10%, we estimate that with at least 15 individuals per treatment group, we will be able to detect a relative increase of a factor of 3 (e.g., 1% mean abundance increased to 4%, or 5% mean abundance increased to 20%), with an expected statistical power of 96.9%.

### 2) Statistical analysis

Raw paired-end 16S rRNA reads (V1V2 region) were merged into consensus fragments by FLASH \[[@B11]\] and subsequently filtered for quality (target error rate \<0.5%) and length (minimum 200 bp) using Trimmomatic and QIIME \[[@B12]\]. Spurious hits to the PhiX control genome were identified using BLASTN and removed. Passing sequences were trimmed of primers, evaluated for chimeras with UCLUST (*de novo* mode), and screened for human-associated contaminant using Bowtie2 followed by a more sensitive BLASTN search against the GreenGenes 16S rRNA database \[[@B13]\]. Chloroplast and mitochondrial contaminants were detected and filtered using the RDP classifier with a confidence threshold of 80%. High-quality 16S rRNA sequences were assigned to a high-resolution taxonomic lineage using Resphera Insight. Differential abundance analysis utilized the nonparametric permutation difference test for alpha diversity or the negative binomial test (DESeq) for taxonomic count data. The p-values were adjusted using the False Discovery Rate (FDR) \[[@B14]\]. Alpha and beta-diversity analyses were performed using QIIME. The Mann-Whitney U test was employed to evaluate statistical significance of beta-diversity distances within and between FQR and FQS groups.

RESULTS
=======

1. Fluoroquinolone resistance
-----------------------------

We collected 131 rectal swab samples from men scheduled to undergo a prostate biopsy, of which 13 (9.9%) were not evaluable. Eight patients did record having antibiotics in the last 6 months and were investigated in the context of those without previous antibiotic use, which did not show a difference (p\>0.05). Of the clinical cultures, we identified 18 isolates (15.5%, 18/116) that were FQR *E. coli* positive ([Fig. 1](#F1){ref-type="fig"}). All bacteria were *E. coli* except one *Klebsiella pneumoniae*. Two of the *E. coli* which were extended beta lactamase producers. Demographics are displayed in [Table 1](#T1){ref-type="table"}. We did note that obesity by measure of body mass index was more prominent in the fluoroquinolone resistant group (p=0.04). No prostate biopsy infections were recorded.

2. Microbiome diversity in FQR+ carriers
----------------------------------------

Men positive for FQR *E. coli* maintained a relatively reduced alpha diversity compared to non-FQR subjects (inverse Simpson; p=0.05). The association of microbial community membership with FQR status was found to be significant for Bray-Curtis (p=0.047) and weighted-UniFrac measures (p=0.01, [Fig. 2](#F2){ref-type="fig"}).

3. Microbiome species analysis
------------------------------

Enterobacteriaceae isolates were significantly overrepresented in the FQR subjects (adjusted p=0.03, [Fig. 3](#F3){ref-type="fig"}). In correlation analysis, we investigate the tope 30 most statistically significant correlations between the dominant *E. coli* signal (*E. coli* Amb1) and other well represented species using non-parametric Spearman correlations (all taxa shows p\<0.004, [Fig. 4](#F4){ref-type="fig"}). We note consistent positive correlations with other Enterobacteriaceae and negative correlations with *Clostridia* and *Bacteroides* members. The bacterial family Aeromonadaceae was absent in the positive FQR culture group despite low relative abundance in non-FQR subjects (adjusted p\<0.001). At the species level, *Prevotella disiens* was significantly enriched in FQR negative subjects (adjusted p=0.012), while *Shigella flexneri* and *Proteus mirabilis* were considerably higher in the FQR positive group (adjusted p=0.017 and adjusted p=0.028, respectively, [Fig. 5](#F5){ref-type="fig"}).

DISCUSSION
==========

Our findings indicate substantial differences in the microbiome comparing those men who are carriers of FQR organisms compared to those who are not. The overgrowth of bacteria, particularly Enterobacteriaceae in those patients colonized with FQR organisms indicate targeting this group of bacteria could be a potential decolonization strategy. A major purpose for our study is to identify the resident microbiome profiles prior to design clinical trials of repurposed pharmaceuticals, prebiotics, or probiotics in this patient population. Considering the only demographic factor significant between the FQR and FQN subjects is body mass index and the link between obesity and the microbiome is well established.

The microbiome has been implicated as a reservoir for antimicrobial resistance and termed the "resistome" \[[@B15]\]. The high density of bacteria allow for communication and sharing of genetic material creating increased likelihood of transfer of microbial resistance. The international metagenomics of human intestinal tract project has identified nearly some 3.3 million different bacterial genes among human microbiomes \[[@B16]\]. The detection of individual groups of gut microbial communities characterized by presence of similar antibiotic resistance profiles has been termed "Resistotypes" similar to the term "Enterotypes" usually describing the dominant microbial bacteria in the gut \[[@B17]\]. One of the particular resistome gene clusters was detected specifically within the European population and contained the *mexb* and *smed* genes imparting resistance to specifically fluoroquinolones \[[@B18]\].

Physicians have had significant concerns regarding the rising fluoroquinolone resistance patterns, specifically in urologic surgical patients. "Targeted prophylaxis" focuses on the detection of FQR organisms before a transrectal prostate biopsy in order to alter antibiotic prophylaxis regimens \[[@B4][@B19]\]. We see this opportunity to also assess for microbiome evaluation and determination of decolonization with various drugs or vaccines could then render the patient free from FQR organisms prior to prostate biopsy. The technique could also be applied to preoperative preparation and recurrent infections. Rather than using more antibiotics, we propose a process in which we could manipulate the microbiome before the prostate biopsy to reduce infection rates. Given our findings, men colonized with FQR *E. coli* have an abundant overgrowth of Enterobacteriaceae and potentially could be targeted utilizing new pharmaceuticals targeting FimH receptors to deplete uropathogenic bacteria and reduce antibiotic-resistant bacteria colonization \[[@B20]\]. In addition to microbiome manipulation with prebiotics or probiotics, vaccines have been previously used against FimH as well \[[@B21][@B22]\]. Vaccines are unlikely to be the future to prevent these infections because newer data have shown that *E. coli* can shed the FimH protein and alter its pathogenic capabilities \[[@B23]\]. With our current data, we are poised to test various subtle microbiome manipulations to attempt to "decolonize" men with fluoroquinolone resistant organisms. In turn, this could lower the hospitalization rate from infection associated with prostate biopsy by four-fold \[[@B24]\]. We anticipate this research would also have implications regarding research in other urologic (prostatitis and recurrent urinary tract infections) and non-urologic disease profiles \[[@B25]\].

Two profiles that favored the absence of FQR organisms were at the family level Aeromonadaceae and *P. disiens*. *Prevotella* has been considered the more favorable or less inflammatory enterotype \[[@B17]\]. Individuals with an enterotype characterized by enriched proportions of *Prevotella* have significantly higher plasma concentration of trimethylamine-*N*-oxide (TMAO) \[[@B26][@B27][@B28][@B29]\]. The biogenic reduction of trimethylamine oxide (TMAO) leads to the metabolite trimethylamine (TMA) to modify the antibiotic resistance profiles of bacteria \[[@B30]\]. Therefore, increasing provetella and/or TMAO may assist with the reduction of antibiotic resistant organisms.

Limitations of the study include a small number of fluoroquinolone resistant subjects and large sample size could provide more robust data for sub-analysis. We also cannot account for the bias from an individual\'s diet, which can alter microbiome composition. We attempt to identify those patients with previous antibiotic use within 6 months because this may alter microbiome results. We did not document probiotic or supplemental use and is rarely documented in the medical record. Probiotic, supplement, and antibiotic use all play important roles in microbiome research and could alter results.

CONCLUSIONS
===========

Microbiome analysis determined that men colonized with FQR bacteria have less diverse bacterial communities, higher levels of Enterobacteriaceae and reduced levels of *P. disiens*. These results may have implications in pre/probiotic or new pharmaceuticals to target Enterobacteriaceae overgrowth with intervention studies.
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###### Demographics
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  Demographic                           FQR positive   FQR negative   p-value
  ------------------------------------- -------------- -------------- ---------
  Sample size                           18             98             
  Race/ethnicity                                                      0.08
   White                                9 (50.0)       50 (51.0)      
   African-American                     1 (5.6)        29 (29.6)      
   Hispanic                             3 (16.7)       17 (17.3)      
   Unknown                              3 (16.7)       5 (5.1)        
  Age                                   65 (61--69)    68 (63--70)    0.2
  Body mass index                       30 (27--33)    28 (25--29)    0.04
  Diabetes                              3 (16.7)       32 (32.7)      0.3
  BPH                                   8 (44.4)       37 (37.8)      0.3
  Previous BPH surgery                  0 (0.0)        2 (2.0)        
  Prostate size on ultrasound           43 (30--63)    37 (29--45)    0.8
  Number of previous biopsies                                         0.4
   1                                    6 (33.3)       21 (21.4)      
   2                                    3 (16.7)       15 (15.3)      
   3+                                   1 (5.6)        4 (4.1)        
  Family history of prostate cancer     5 (27.8)       20 (20.4)      0.5
  Diagnosed with prostate cancer        8 (44.4)       55 (56.1)      0.7
  Antibiotic use within last 6 months   2 (11.1)       6 (6.1)        0.6

Values are presented as number only, number (%), or median (interquartile range).

FQR, fluoroquinolone-resistant; BPH, benign prostate hypertrophy.
